FDA Commissioner Marty Makary Resigns Over Policy Moves
SkimNews Take
Makary's rapid policy shifts and ad-hoc panels, while aiming for speed, inadvertently eroded the institutional trust necessary for an agency whose power relies on public and scientific consensus.
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Marty Makary resigned as FDA commissioner on Tuesday, creating a top‑level vacancy.
- Marty Makary, Robert F. Kennedy Jr., and Jay Bhattacharya announced on X that the COVID‑19 vaccine would no longer be routinely recommended for healthy pregnant women and children.
- Marty Makary and deputy Vinay Prasad overruled FDA staff scientists, preferring press releases and journal commentaries over formal agency rulings.
- Marty Makary convened ad‑hoc “rubber‑stamp” panels rather than proper advisory committees to endorse administration policies.
- Marty Makary launched a “Commissioner’s National Priority Voucher” to accelerate drug application reviews.
Why it matters: The FDA loses stable leadership, potentially delaying drug approvals and eroding public trust, while industry groups may gain short‑term fast‑track access but face longer‑term regulatory uncertainty.
